As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?


Created by

 CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Paul Ridker, MD

Paul Ridker, MD

Atherosclerosis Prevention Paul Ridker, MD, Eugene Braunwald Professor Harvard Medical School Division of Cardiovascular Medicine Director, Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital Boston, MA